1022152-70-0 Usage
Uses
Used in Pharmaceutical Industry:
MK-5046 is used as a therapeutic agent for improving insulin sensitivity and glucose metabolism, primarily targeting the treatment of type 2 diabetes and metabolic disorders. Its ability to modulate these key metabolic processes makes it a valuable asset in managing and potentially reversing the effects of these conditions.
Used in Anti-Inflammatory Applications:
MK-5046 is utilized as an anti-inflammatory agent, addressing conditions associated with chronic inflammation. Its demonstrated anti-inflammatory properties suggest that it could be an effective treatment for a range of inflammatory diseases, potentially reducing inflammation and associated symptoms.
Used in Drug Development:
MK-5046 serves as a novel drug candidate for further development and clinical testing. Its dual action as both a metabolic regulator and an anti-inflammatory agent makes it a promising compound for the exploration of new treatment options for a variety of diseases and disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 1022152-70-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,2,1,5 and 2 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1022152-70:
(9*1)+(8*0)+(7*2)+(6*2)+(5*1)+(4*5)+(3*2)+(2*7)+(1*0)=80
80 % 10 = 0
So 1022152-70-0 is a valid CAS Registry Number.
1022152-70-0Relevant academic research and scientific papers
Discovery of MK-5046, a potent, selective bombesin receptor subtype-3 agonist for the treatment of obesity
Sebhat, Iyassu K.,Franklin, Christopher,Lo, Michael M.-C.,Chen, David,Jewell, James P.,Miller, Randy,Pang, Jianmei,Palyha, Oksana,Kan, Yanqing,Kelly, Theresa M.,Guan, Xiao-Ming,Marsh, Donald J.,Kosinski, Jennifer A.,Metzger, Joseph M.,Lyons, Kathryn,Dragovic, Jasminka,Guzzo, Peter R.,Henderson, Alan J.,Reitman, Marc L.,Nargund, Ravi P.,Wyvratt, Matthew J.,Lin, Linus S.
supporting information; experimental part, p. 43 - 47 (2011/04/17)
We report the development and characterization of compound 22 (MK-5046), a potent, selective small molecule agonist of BRS-3 (bombesin receptor subtype-3). In pharmacological testing using diet-induced obese mice, compound 22 caused mechanism-based, dose-
Substituted inmidazoles as bombesin receptor subtype-3 modulators
-
Page/Page column 48-49, (2010/02/17)
Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
